Skip to main content
. 2014 Jul 26;54(11):1944–1953. doi: 10.1093/rheumatology/keu285

Fig. 2.

Fig. 2

Current management of digital vasculopathy in SSc

Treatment approaches may target individual pathological processes in SSc and include agents that are undergoing clinical evaluation or may have potential. Anti-fibrotic strategies are currently less developed than vascular or immunological candidate therapies. *If indicated. MRA: magnetic resonance angiography; CCB: calcium channel blocker; ARB: angiotensin receptor blocker. Modified from the Royal Free Hospital protocol.